SeQuent Scientific reports strong growth, merger with Viyash Group approved

SeQuent Scientific Limited announced strong financial performance for Q2 FY '26, with total revenue reaching INR4,240 million, marking a 15% year-on-year growth. The formulation segment contributed INR3,351 million, an 18% increase, while the API segment grew 7% to INR830 million. Gross margin improved by 270 basis points to 49.7%, and adjusted EBITDA rose 47% to INR657 million, achieving a 15.5% margin. Profit after tax nearly tripled to INR196 million from INR63 million in the same quarter last year.

For the first half of FY '26, total revenue was INR8,654 million, up 14% year-on-year. Adjusted EBITDA for H1 FY '26 was INR1,259 million, a 35.4% increase, with margins expanding to 14.5%. Profit after tax more than doubled to INR372 million.

The National Company Law Tribunal (NCLT) approved the merger between SeQuent and the Viyash Group on November 18, 2025. Viyash reported Q2 FY '27 revenue of INR428 crores, a 17.8% year-on-year growth, and EBITDA of INR123 crores, up 96%, with margins at 28.8%. The combined entity's Q2 revenue was INR852 crores, growing 16% year-on-year, with an EBITDA of INR189 crores and margins improving to 22%.